A novel antibody targeting sequence 31-35 in amyloid β protein attenuates Alzheimer's disease-related neuronal damage

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's disease (AD) pathogenesis involves amyloid-beta (Aβ) protein.
• The Aβ sequence 31-35 is identified as a key neurotoxic center.
• Developing targeted therapies for AD is a critical research area.

Purpose of the Study:

• To develop and evaluate a novel antibody targeting the Aβ 31-35 sequence.
• To investigate the neuroprotective potential of this anti-Aβ₃₁₋₃₅ antibody against Aβ₁₋₄₂-induced neurotoxicity.
• To assess the antibody's efficacy in improving neuronal viability, spatial memory, and hippocampal synaptic plasticity.

Main Methods:

• Preparation of a specific antibody targeting the Aβ 31-35 sequence.
• In vitro assessment of antibody binding affinity to Aβ₃₁₋₃₅ and Aβ₁₋₄₂.
• Evaluation of antibody's effect on Aβ₁₋₄₂-induced cytotoxicity in cultured cortical neurons.
• In vivo studies using rat models involving intracerebroventricular injections and behavioral/electrophysiological assessments.

Main Results:

• The anti-Aβ₃₁₋₃₅ antibody demonstrated effective binding to both Aβ₃₁₋₃₅ and Aβ₁₋₄₂.
• Antibody pretreatment dose-dependently protected cultured neurons from Aβ₁₋₄₂-induced cytotoxicity.
• Intracerebroventricular administration of the antibody attenuated Aβ₁₋₄₂-induced spatial learning and memory impairments in rats.
• Electrophysiological data confirmed the antibody's ability to reverse Aβ₁₋₄₂-induced suppression of hippocampal synaptic plasticity.

Conclusions:

• The Aβ 31-35 sequence represents a promising therapeutic target for Alzheimer's disease.
• The developed anti-Aβ₃₁₋₃₅ antibody shows significant neuroprotective effects.
• This antibody presents a potential novel immunotherapeutic strategy for AD treatment.